Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first commercial production of Axumin in Belgium occurred recently, with the first Belgian patients being dosed. This follows the first administration of Axumin in Luxembourg earlier this year. Axumin is the first and only positron emission tomography (PET) imaging agent approved in the European Union for use in men with suspected recurrent prostate cancer. Axumin is commercially available in Belgium, Luxembourg, Italy, France, Norway, the Czech Republic, The Netherlands, United Kingdom and Austria, with further European countries set to follow soon.
NVIDIA and King’s College London announced they are partnering to build an artificial intelligence (AI) platform that will in the near future allow specialists in the U.K.’s National Health Service (NHS) to train computers to automate the most time-consuming part of radiology interpretation.
At ASTRO 2018, Accuray showcased new patient-first innovations, including motion synchronization on Radixact, and the ...
Fujifilm’s APERTO Lucent is a 0.4T mid-field, open MRI system addressing today’s capability and image quality needs ...
Zebra Medical Vision has received U.S. Food and Drug Administration (FDA) 510(k) clearance for HealthPNX, an artificial intelligence (AI) alert for pneumothorax (PNX) based on chest X-rays.
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a magnetic resonance imaging (MRI) ablation center for treating cardiac arrhythmias.
SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...
The integration of artificial intelligence (AI) into medicine has by far been the hottest topic at nearly all medical ...
SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy after chemotherapy, even when all traces of the cancer appear to have gone. These findings are according to late-breaking results presented at the European Society for Radiotherapy and Oncology (ESTRO) 38 conference, April 26-30 in Milan, Italy.
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain and Telemis aimed at accelerating installation, optimizing service and improving clinical operations for proton therapy.
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S. Department of Energy (DOE) Under Secretary for Nuclear Security and Administrator of the National Nuclear Security Administration (NNSA) Lisa Gordon-Hagerty, Lantheus Medical Imaging President and CEO Mary Heino and Janesville City Manager Mark Freitag joined Shine founder and CEO, Greg Piefer, and the Shine team to celebrate the milestone.
SPONSORED CONTENT — EnsightTM 2.0 is the newest version of Enlitic’s data standardization software framework. Ensight is ...
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has ...
Imaging Technology News (ITN) earned an Honorable Mention at the 2019 National Azbee Awards of Excellence in the Cross-Platform Package of the Year category for its coverage of the ITN editorial team’s visit to Central DuPage Hospital in Winfield, Ill.
When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast cancer and avoid unnecessary biopsies, according to a new study. The findings were presented at the American Roentgen Ray Society (ARRS) 2019 Annual Meeting, May 5-10 in Honolulu.
Did you know that approximately one-third of all the data in world is created by the healthcare industry and that ...
I miss the days when the difference between meaningful and meaningless was apparent; when the line separating relevant ...
May 9, 2019 — A new clinical trial at The Ohio State University Wexner Medical Center and two other sites is testing an ...
SPONSORED CONTENT — EnsightTM 2.0 is the newest version of Enlitic’s data standardization software framework. Ensight is ...
The DigitalDiagnost C90 is Philips newest premium digital radiography (DR) system, introduced here at the Radiological ...
Radiation kills tumors by creating oxygen free radicals that damage the tumor DNA. However, the lack of oxygen in the center of tumors blocks the production of free radicals, inhibiting radiation killing. NIBIB researchers have now designed a nanoparticle that generates radiation-induced oxygen free radicals even in the low-oxygen center of tumors, dramatically increasing the success of radiation therapy.
May 8, 2019 — Carestream introduced its ImageView Software Platform Windows 10 operating system to deliver enhanced ...
May 8, 2019 – United Imaging Healthcare (UIH), an international leader in advanced medical imaging and radiotherapy equipment, announced its U.S. Food and Drug Administration (FDA) clearance of the uPMR 790 HD TOF PET/MR. uPMR 790 redefines clinical routine imaging for PET/MR with the capability to scan a whole body within 20 minutes, balancing patient comfort with high-quality imaging.
Researchers from two major institutions have developed a new tool with advanced artificial intelligence (AI) methods to predict a woman's future risk of breast cancer, according to a new study published in the journal Radiology.
Philips announced that telehealth service provider Chipmunk Health, with locations in the Netherlands and Canada, is leveraging the capabilities and services of Philips’ HealthSuite digital platform to roll out its new GP-to-patient home monitoring solutions.